Biotechnology - Live Biotherapeutics / Microbiome Therapeutics
Strategic Profile
Seres has implemented a corporate strategy to advance its live biotherapeutic programs in inflammatory and immune diseases, with a focus on inflammatory bowel disease and immune checkpoint-related enterocolitis. The company has reduced workforce by approximately 30% to extend cash runway through Q3 2026, pausing additional investment in the SER-155 Phase 2 transplant program while prioritizing early-stage inflammatory disease programs.
Cyborg Score Rationale
The company has a market cap of $71.78 million as of February 17, 2026. With cost-reduction measures including 30% workforce reduction, cash runway is expected to extend through Q3 2026. Seres is a clinical-stage biotech with limited revenue, pending Phase 2 clinical data, and significant liquidity constraints.
Top Insights
Richard N. Kender was appointed as Executive Chair and Interim CEO as of March 2, 2026, bringing over 35 years of biopharma executive experience including a senior role at Merck & Co.
SER-155 investigator-sponsored trial in immune checkpoint-related enterocolitis is fully enrolled with initial data expected in early Q2 2026, representing a near-term binary catalyst.
Cash runway is expected to extend through Q3 2026, creating urgency for funding and partnership opportunities to advance pipeline programs.
Successful VOWST approval and subsequent sale to Nestlé validates microbiome therapeutic approach and provides strategic precedent for live biotherapeutic platform.
Named Competitors
Fate Therapeutics — Cell therapy and immunotherapy company developing off-the-shelf cellular therapies
Vir Biotechnology — Antiviral and immunotherapy company with infectious disease focus
Altimmune — Immunology company developing intranasal vaccines and therapeutics
Recent Developments
(March 2026) Richard N. Kender appointed Executive Chair and Interim CEO; co-CEOs transitioned to CLO/CFO roles
(February 2026) 30% workforce reduction implemented to extend cash runway through Q3 2026; SER-155 Phase 2 allo-HSCT program paused
(Q2 2026 Expected) SER-155 irEC investigator-sponsored trial data readout announced
(November 2025) Q3 2025 cash position $47.6M; company expects to fund operations through Q2 2026
Open the full interactive Seres Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.